Syntone Ventures LLC - Apr 15, 2024 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Role: 10%+ Owner
Signature: /s/ Jiahui Zheng, Attorney-in-Fact
Stock symbol: OTLK
Transactions as of: Apr 15, 2024
Transactions value $: $0
Form type: 4
Date filed: 4/17/2024, 08:21 PM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OTLK	Common Stock	Purchase		+714K	+72.07%		1.71M	Apr 15, 2024	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OTLK	Warrant (Right to Buy)	Purchase		+1.07M			1.07M	Apr 15, 2024	Common Stock	1.07M	$7.70	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Acquired in a private placement transaction pursuant to the terms of the Securities Purchase Agreement (the "SPA"), dated as of January 22, 2024, between Outlook Therapeutics, Inc. (the "Issuer") and Syntone Ventures LLC ("Syntone"), pursuant to which the Issuer sold shares of common stock, and, for each such share of common stock, accompanying warrants to purchase up to one and a half shares of common stock, at a purchase price of $7.00 per share and accompanying warrant. Under the SPA, Syntone purchased 714,286 shares of common stock and warrants to acquire 1,071,429 shares of common stock closed on April 15, 2024.
F2	Effective March 14, 2024, every 20 issued and outstanding shares of the Issuer's common stock was automatically combined into one issued and outstanding share of the Issuer's common stock (the "Reverse Stock Split"). Prior to the Reverse Stock Split, Syntone held 19,823,045 shares of common stock and, as a result of the Reverse Stock Split, such shares of common stock became 991,152 shares of common stock.

Content

Acquired in a private placement transaction pursuant to the terms of the Securities Purchase Agreement (the "SPA"), dated as of January 22, 2024, between Outlook Therapeutics, Inc. (the "Issuer") and Syntone Ventures LLC ("Syntone"), pursuant to which the Issuer sold shares of common stock, and, for each such share of common stock, accompanying warrants to purchase up to one and a half shares of common stock, at a purchase price of $7.00 per share and accompanying warrant. Under the SPA, Syntone purchased 714,286 shares of common stock and warrants to acquire 1,071,429 shares of common stock closed on April 15, 2024.

Effective March 14, 2024, every 20 issued and outstanding shares of the Issuer's common stock was automatically combined into one issued and outstanding share of the Issuer's common stock (the "Reverse Stock Split"). Prior to the Reverse Stock Split, Syntone held 19,823,045 shares of common stock and, as a result of the Reverse Stock Split, such shares of common stock became 991,152 shares of common stock.